Faruqi & Faruqi, LLP Files Class Action Lawsuit Against Keryx Biopharmaceuticals, Inc. -- KERX

NEW YORK, Feb. 1, 2013 /PRNewswire/ -- Notice is hereby given that Faruqi & Faruqi, LLP has filed a class action lawsuit in the United States District Court for the Southern District of New York, case no. 13 Civ. 0755, on behalf of all persons who purchased Keryx Biopharmaceuticals, Inc. ("Keryx" or the "Company") (NASDAQ CM: KERX) securities between June 1, 2009 and April 1, 2012 inclusive (the "Class Period").

(Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO )

If you wish to obtain information concerning this action or view a copy of the complaint, you can do so by clicking here: www.faruqilaw.com/KERX

Keryx and its Chief Executive Officer Ron Bentsur are alleged to have violated Section 10(b) and/or 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. Specifically, the complaint alleges that defendants mislead investors about the timing and success of Keryx's clinical trial that tested whether the drug perifosine was effective in treating late stage colorectal cancer.